( ext day functioning in insomnia patien...)Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia,Health

ext day functioning" in insomnia patients to determine if these tests were successful in measuring key impairment characteristics. -- The research identified impairment in several areas that were not identified by traditional tests of functioning. Examples include abstraction, organization/planning, time management, cognitive flexibility, judgment and problem solving. -- Researchers concluded that current measures of daytime functional impairment may not accurately assess key aspects of daytime functional impairment.

Increase in Medical Errors As a Result of Insomnia

Results of a new survey that found that insomnia was common in the nursing community, previously announced by Alertness Solutions, were presented at the APSS meeting. The authors concluded that more than one quarter of nurses surveyed suffered from insomnia. The survey conducted by Dr. Mark Rosekind, founder, president and chief scientist of Alertness Solutions, previous director of the Fatigue Countermeasures Program at the NASA Ames Research Center and sleep researcher at Stanford University also identified potential daytime consequences of insomnia that were common among nurses that may affect patient care including a significant increase in medication dispensing errors, charting deviations, and falling asleep unintentionally at work.

Neurocrine is developing indiplon for the treatment of insomnia. Indiplon was licensed from DOV Pharmaceutical in 1998. Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. The product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, endometriosis, irritable bowel syndrome, and pain. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at

Page: 1 2 3 4 5
Related medicine technology :

1. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
2. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
3. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone